SCHEMBL14927286

SCHEMBL14927286

Cn1c(=O)[nH]c2ccc(C(=O)c3nc(Br)c4ccccn34)cc2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.41
ADORA2B P29275 2/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
LMNA P02545 1/20 0.36
BRD4 O60885 1/20 0.35
HTR3A P46098 1/20 0.35
SSTR4 P31391 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
ATM Q13315 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
PARG Q86W56 1/20 0.34
RORC P51449 4/20 0.33
HPD P32754 1/20 0.33
MAPT P10636 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
AURKA O14965 3/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322579 0.88 NPC1 (0.41) ADORA3ADORA2BADORA1LMNAHTR3A
SCHEMBL14927292 0.82 ALDH1A1 (0.43) BRD4KDM4EGLAATMRXFP1
SCHEMBL14916222 0.82 F2 (0.39) SSTR4RORCFNTAFNTB
SCHEMBL14916387 0.81 HPGD (0.46) LMNAHTR3AKDM4ERXFP1MAPT
SCHEMBL14927289 0.80 ADORA3 (0.43) ADORA3ADORA2BADORA2AADORA1LMNA
SCHEMBL322542 0.80 KCNH2 (0.39) LMNAKDM4EGLAMAPT
SCHEMBL14916533 0.77 ALDH1A1 (0.43) SSTR4KDM4EGLAATMRXFP1
SCHEMBL14927297 0.77 MAPT (0.40) LMNAKDM4EGLARORCHPD
SCHEMBL323368 0.76 NPC1 (0.43) ADORA3ADORA2BADORA1LMNAHTR3A
SCHEMBL9760930 0.75 ADORA3 (0.56) ADORA3ADORA2BADORA2AADORA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ADORA3 295/4885ADORA2B 380/4885ADORA2A 1199/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 ADORA3 285/4885ADORA2B 673/4885ADORA2A 1806/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH ADORA3 295/4885ADORA2B 380/4885ADORA2A 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.